Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Vasiliki K. Katsi, Christos A. Michalakeas, Charalambos E. Grassos, Georgia D. Vamvakou, John P. Lekakis, Dimitris Tousoulis, Christodoulos I. Stefanadis, Thomas K. Makris and Ioannis E. Kallikazaros
Affiliation: Cardiology Department, Hippocratio Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.
Keywords: Anti-diabetics, canagliflozin, hyperglycemia, invokana, sodium-glucose cotransporter-2 (SGLT2) inhibitors, type 2
Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known
as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of
glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several
phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This
review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in
the treatment of type 2 diabetes mellitus.
Rights & PermissionsPrintExport